Skip to main content
Menu
US

Naloxone, [N-allyl-2,3,-3H]-

Naloxone radioligand tritiated at the 2,3 position. Naloxone acts as a non-selective, competitive opioid receptor antagonist.

For research use only. Not for use in diagnostic procedures

Part number: NET719250UC
List price: USD 6,704.00
Your price: Login to view
USD 6,704.00
USD 6,704.00 /each

Overview

Naloxone functions as a non-selective, competitive antagonist at opioid receptors. It commonly used to reverse the effects of opioid overdose and to prevent opioid abuse.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET719:

  1. Andrei Sonnabend, Viola Spahn, Marlitt Stech, Anne Zemella, Christoph Stein, Stefan Kubick. Production of G protein-coupled receptors in an insect-based cell-free system. Biotechnology and Bioengineering. October 2017. Volume 114, Issue 10, pages 2328-2338.
  2. Peter Heusler, Stephanie Tardif, Didier Cussac. Agonist stimulation of human µ opioid receptors in a [35S]GTPγS incorporation assay: observation of “bell-shaped” concentration-response relationships under conditions of strong receptor G protein coupling. Journal of Receptors and Signal Transduction. 2016. Volume 36, Issue 2, pages 158-166.
  3. Michael B Gatch, Alexey Kozlenkov, Ren-Qi Huang, Wenjuan Yang, Jacques D Nguyen, Javier Gonzalex-Maeso, Kenner C Rice, Charles P France, Glenn H Dillon, Michael J Forster, John A Schetz. The HIV Antiretroviral Drug Egavierenz has LSD-like Properties. Neuropsychopharmacology. May 2013.

Specifications

Application
Drug Discovery & Development
Brand
NEN Radiochemicals
Detection Method
Radiometric
Label Position
Nominally Labeled
One Unit Contains
250.0 µCi
Radioisotope
3H
Receptor Type
Opioid
Shipping Conditions
Shipped in Dry Ice
Special Ordering Information
This is a radioactive product - shipping address must have a license to receive radioactive materials.
Therapeutic Area
CNS & Neurologic
Inflammation
Pain
Unit Size
250 µCi

Resources

1-1 of 1 Resources
Calendar Icon
Calendar
2024 Fresh Lot Calendar

SDS, COAs, Manuals and more

Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.

Safety data sheet
+ Show more
Technical data sheet
+ Show more
Scroll Icon